

## **ASX Announcement**

### **Imugene's CF33 Oncolytic Virus (MAST) study to be showcased at SITC Annual Meeting**

---

Sydney, Australia, 3 August 2023: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce that its CF33 Oncolytic Virus technology will be featured at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC), to be held in San Diego, USA on 1-5 November 2023.

As one of the most prestigious immunotherapy events on the calendar, SITC 2023 features cutting-edge research presentations by various experts, oral, and poster abstract presentations and various opportunities for networking and discussion with members of the oncology community.

The CF33 technology has been accepted for a Trial-in-Progress Poster titled: A Phase I Safety and Tolerability Study of VAXINIA (CF33-hNIS), a Novel Chimeric Oncolytic Poxvirus, Administered Intratumorally or Intravenously in Adults with Metastatic or Advanced Solid Tumors.

Abstract #: 730

Imugene will announce further details from this abstract closer to the time of the event.

For more about SITC 2023, please visit: <https://www.sitcancer.org/2023/home>

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
[info@imugene.com](mailto:info@imugene.com)

**Investor Enquiries**  
[shareholderenquiries@imugene.com](mailto:shareholderenquiries@imugene.com)



## **Media Enquiries**

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

## **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.*